Oculis is a clinical stage ocular therapeutics company focusing on innovative topical treatments (eye drops) for both back and front of the eye diseases. The company's treatments are based on its proprietary Solubilizing Nanoparticle (SNP) technology, which makes it easier to formulate drugs into eye drops and also enhances their penetration into the deeper tissues of the eye. Oculis' lead program is OC-118, an SNP based formulation of dexamethasone being developed for Diabetic Macular Edema, one of the leading causes of blindness in diabetics. Oculis is led by experienced former executives from leading eyecare company Alcon, and is headquartered in Switzerland.
{}